Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris’ Mylan And Apotex Lose Again Over US Bendeka Patents

ANDA Sponsors Continue To Be Barred From Launch Until 2031

Executive Summary

Viatris’ Mylan and Apotex once again fell to Teva and Eagle Pharmaceuticals in their battle to introduce generic versions of the rapid-infusion bendamustine formulation, Bendeka, with the US Federal Circuit upholding a lower court judgement.

You may also be interested in...



Eagle Will Be Last Firm To Bypass FDA's Orphan Drug Exclusivity Requirement

Court orders US FDA to award Bendeka seven years of exclusivity without requiring clinical superiority test; law codifying FDA policy passed prior to suit and is not retroactive.

Eagle Hopes To Build On Bendamustine Success With Injectable Reformulations

With concentrated, lower-volume injectables, the specialty firm is finding larger patient bases for the cancer drug bendamustine and the muscle relaxant dantrolene.

Three Not A Magic Number For Mayne With Another NuvaRing CRL

Australia’s Mayne Pharma has announced another complete response letter for its proposed generic version of Organon’s NuvaRing (etonogestrel/ethinylestradiol) contraceptive device, marking a trio of setbacks for the ANDA product.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151178

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel